Compare Abeona Therapeutics Inc (ABEO) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Avantis US Small Cap Value ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Avantis US Small Cap Value ETF trades at $122.17. Which is the better fit depends on your goals.
| ABEO | AVUV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $124.94 |
52-Week Low | $4.17 | $90.37 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AVUV trades at $123.82, up 0.25% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF's small-cap value focus has gained attention amid a market rotation, with recent news highlighting its outperformance versus growth peers and potential benefits from shifting rate expectations. Support and resistance levels are closely watched near current prices.
The outlook for AVUV hinges on continued small-cap value strength, though exposure to regional banks and sensitivity to interest rates pose risks. Its active management approach aims to capture the value premium, but elevated volatility relative to large-caps remains a consideration for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
